RegeneRx Receives Mexican Patent for the Use of TB4 for Prevention, Treatment of Cardiac Damage

RegeneRx Biopharmaceuticals, Inc. announced Thursday that the Company received a patent from the Mexico Patent and Trademark Office for the use of thymosin beta 4, its analogues, isoforms, and other derivatives, for preventing or healing the damage that occurs from a myocardial event, or heart attack.
TheStreet